Celltrion Launches Liquid Remsima IV in Europe to Lead Infliximab Market

Celltrion has introduced the new liquid formulation of Remsima IV in Europe, aiming to bolster its global leadership in the infliximab therapeutic market and meet healthcare provider needs more effectively. The announcement represents a significant step in the company’s strategy to expand its competitive position in the global autoimmune disease treatment sector.

According to the official statement, the liquid version of Remsima IV is currently the only formulation owned exclusively by Celltrion, protected by related patents. By offering this innovative formulation, Celltrion expects to address clinical and logistical demands, thereby enhancing patient access and improving product usability in healthcare settings across Europe.

The injectable infliximab biosimilar Remsima has long been recognized as a cornerstone treatment for autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Now, the new liquid formulation of Remsima IV is expected to strengthen the product’s impact by making administration more convenient and efficient for medical professionals in hospitals and clinics.

Remsima IV’s success in Europe has been notable, especially after gaining regulatory approval for the liquid formulation last November. Celltrion’s Nordic subsidiary quickly capitalized on this approval by successfully securing national tenders in Denmark and Norway, enabling immediate sales and distribution. This early market success is projected to secure approximately 35% of Norway’s infliximab IV market through 2028, positioning Remsima IV as a leading choice for intravenous treatment.

By expanding options beyond the existing lyophilized Remsima IV and the subcutaneous Remsima SC formulation, Celltrion aims to offer healthcare providers a full lineup that accommodates varying clinical and storage preferences. Healthcare professionals have emphasized the need for a multidose liquid formulation to improve storage efficiency and reduce preparation time, a requirement that the new liquid Remsima IV satisfies.

Industry analysts note that the liquid Remsima IV formulation could significantly benefit healthcare facilities, as it can reduce preparation time by nearly 50% while cutting labor and consumable expenses by roughly 20%. Furthermore, the new format promises to reduce storage space and associated costs by up to 70%, presenting a compelling value proposition for hospitals and clinics across Europe.

As competition in the global biosimilar market intensifies, Celltrion’s launch of the Remsima IV liquid formulation signals a proactive strategy to differentiate its products and capture broader market demand. Many healthcare stakeholders see this development as a key competitive advantage, particularly in regions where ease of use and supply chain efficiency are critical considerations in drug selection.

Following the successful tender win in Norway, Celltrion plans to expand the rollout of the liquid Remsima IV to other European markets, including France, the Netherlands, and the Czech Republic. This broader launch underscores the company’s commitment to driving deeper market penetration and strengthening the Remsima IV brand across diverse healthcare systems.

Celltrion reports that the expanded product portfolio now positions the company uniquely in the global infliximab market, offering both intravenous and subcutaneous formats under the Remsima family. This comprehensive approach is expected to attract greater adoption and loyalty among prescribing physicians and patients alike.

A company spokesperson emphasized that the liquid Remsima IV formulation reflects Celltrion’s ongoing efforts to innovate and respond to evolving clinical needs. By maintaining a field-centric perspective, the company continues to tailor its sales and marketing activities to deliver better treatment outcomes and operational efficiencies for healthcare providers.

In market performance terms, the Remsima product line, encompassing both IV and SC formulations, maintained a leading position in Europe with an approximate 68% prescription market share as of the third quarter of last year. With the introduction of the liquid Remsima IV, Celltrion expects to sustain and potentially increase this dominant share, reinforcing its foothold in the autoimmune therapy segment.

Looking ahead, Celltrion plans to continue expanding its Remsima portfolio and pursue additional product innovations that address unmet needs in autoimmune disease treatment. This strategic focus aligns with the company’s broader vision of strengthening its global market presence and delivering high-quality products. quality biosimilar therapies that improve patient care worldwide.